* Four banks to split most of estimated $100-$125 mln fees
* Nine-month saga ends in takeover worth $20.1 bln-plus
(Adds Credit Suisse banker name in paragraph 8)
By Quentin Webb and Jessica Hall
LONDON/PHILADELPHIA, Feb 16 Banks including
Goldman Sachs and JPMorgan stand to earn up to $125 million in
fees after Sanofi-Aventis SA finally clinched a $20.1
billion-plus deal to buy Genzyme Corp. [ID:nLDE71F046]
Sanofi's (SASY.PA) banks may receive $50 million to $60
million for their mergers and acquisitions (M&A) advice, while
Genzyme's GENZ.O financial advisers could make $53 million to
$65 million, according to estimates by Freeman & Co, a
Sanofi's lead financial advisers were Evercore Partners
(EVR.N) and JPMorgan Chase & Co (JPM.N), while Credit Suisse
CSGN.VX and Goldman Sachs (GS.N) advised Genzyme, Sanofi said
Evercore's banking team included Francois Maisonrouge and
Evercore founder and Chairman Roger Altman, as well as John
Honts, Jeff Goater, Fausto Borotto and Eddy Kim.
Maisonrouge, the son of former IBM executive Jacques
Maisonrouge, previously worked on deals such as advising Wyeth
on its sale to Pfizer Inc and advising TPG on its acquisition
of IMS Health.
Maisonrouge joined the boutique in 2007 after 15 years at
Credit Suisse, where he worked with clients such as Johnson &
Johnson, Schering-Plough, Wyeth, GlaxoSmithKline, Roche and
Sanofi's team at JPMorgan was led by Robbie Huffines and
included Henry Gosebruch, Isabelle Seillier and Laurent Dhome.
Genzyme's team at Credit Suisse included Vice Chairman
Scott Lindsay, as well as Stuart Smith, Brian Gudofsky and
The Goldman Sachs banking team included Marshall Smith,
Jack Levy, Jason Silvers and William Anderson.
BNP Paribas (BNPP.PA) and Societe Generale (SOGN.PA), which
along with JPMorgan arranged $15 billion of loans for Sanofi,
will reap separate lending fees and may also receive M&A fees.
So too could Morgan Stanley (MS.N). In November, sources
familiar with the matter said Sanofi had hired the Wall Street
bank as an additional adviser. [ID:nN15264829]
The law firm Weil, Gotshal & Manges LLP advised Sanofi,
while Ropes & Gray LLP advised Genzyme. Wachtell, Lipton, Rosen
& Katz advised Genzyme's independent directors.
Companies rarely disclose M&A fees or "all-in merger
costs," a much bigger figure that includes fees paid to
lenders, lawyers, accountants, printers and others.
However, U.S. Securities and Exchange Commission filings
provide some recent examples in healthcare.
Last year Millipore, a U.S. maker of biotechnology tools,
agreed to pay up to $33 million to Goldman Sachs for advice on
its $6 billion sale to Germany's Merck KGaA (MRCG.DE), while
JPMorgan earned $21.7 million advising Biovail Corp of Canada
on its tie-up with Valeant Pharmaceuticals International
(Reporting by Quentin Webb in London and Jessica Hall in
Philadelphia; Editing by David Cowell, John Wallace and Steve